Crosspoint Capital Strategies’s GSK GSK Stock Holding History

Crosspoint Capital Strategies’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,150	Closed	-$61K	–	399
2015 Q4	$61K	Buy	1,150 +926	+413%	+$47.2K	0.02%	409
2015 Q3	$11K	Sell	224 -9	-4%	-$469	0.01%	395
2015 Q2	$12K	Hold	233	–	–	﹤0.01%	468
2015 Q1	$13K	Sell	233 -4,292	-95%	-$246K	0.01%	378
2014 Q4	$242K	Sell	4,525 -26	-0.6%	-$1.46K	0.08%	175
2014 Q3	$262K	Buy	4,551 +189	+4%	+$11.6K	0.19%	86
2014 Q2	$263K	Buy	4,362 +36	+0.8%	+$2.44K	0.1%	117
2014 Q1	$289K	Hold	4,326	–	–	0.12%	105
2013 Q4	$305K	Buy	+4,326	New	+$281K	0.1%	114

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Crosspoint Capital Strategies's GSK Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of GSK (GSK) in Q1 2016, closing a stake of 1,150 shares — an estimated $61K sold.

Crosspoint Capital Strategies first reported a position in GSK in Q4 2013 and held it in 9 quarters. The position peaked at $305K in Q4 2013. 726 funds tracked by Wall St. Rank hold GSK as of Q1 2016.

Crosspoint Capital Strategies reported no remaining GSK position as of Q1 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 1,150 GSK shares in Q1 2016, an estimated $61K.
Crosspoint Capital Strategies first reported a position in GSK in Q4 2013 and held it in 9 quarters.
Crosspoint Capital Strategies's GSK position peaked at $305K in Q4 2013.
726 funds tracked by Wall St. Rank held GSK as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.